EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Preemptive cyclosporin A in immune‐mediated thrombotic thrombocytopenic purpura

Celine Comparon, Lionel Galicier, Jean Michel Rebibou, Paul Coppo, Ygal Benhamou

European Journal of Haematology · 2023-02 · 110 (2) · 157-160

DOI: 10.1111/ejh.13886 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 14.11.2022. Verfasst von Celine Comparon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Référence des Microangiopathies Thrombotiques (CNR-MAT), AP-HP, Paris, France. Hauptthemen laut MEDLINE: Cyclosporine, Purpura, Thrombotic Thrombocytopenic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Survivors of immune‐mediated thrombotic thrombocytopenic purpura (iTTP) are exposed to clinical relapses when a disintegrin and metalloproteinase with thrombospondin type 1 repeats, member 13 (ADAMTS13) activity decreases during follow‐up. Although preemptive rituximab usually improves ADAMTS13 activity in this context, 15% of patients experience refractoriness or intolerance to rituximab and require alternative strategies. Here, we addressed whether cyclosporine A (CSA) could improve ADAMTS13 activity and prevent clinical relapses in this context. We treated preemptively with CSA 14 iTTP patients who were unresponsive ( n = 11) or intolerant ( n = 3) to rituximab. All patients had a severe ADAMTS13 deficiency (activity

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclosporinePurpura, Thrombotic ThrombocytopenicHumansRituximabAutoantibodiesADAMTS13 ProteinRecurrence

Stichwörter der Autor:innen

ADAMTS 13 activitycyclosporine Aimmunologythrombotic thrombocytopenic purpura

Substanzen

RituximabCyclosporineAutoantibodiesADAMTS13 Protein

Autor:innen und Institutionen

  • Centre de Référence des Microangiopathies Thrombotiques (CNR-MAT), AP-HP, Paris, France.
  • Service de Médecine Interne, CHU Avicenne, Bobigny, France.
  • Service de Médecine Interne, Hôpital Saint Joseph, Marseille, France.
  • Service de Néphrologie, Transplantation Hémodialyse, CHU, Dijon, France.
  • Service d'Hématologie, APHP and Sorbonne Université, Paris, France.
  • INSERM UMRS1138, Centre de Recherche des Cordeliers, Paris, France.

Zitieren

APA

Comparon, C., Galicier, L., Rebibou, J. M., Coppo, P., & Benhamou, Y. (2023). Preemptive cyclosporin A in immune‐mediated thrombotic thrombocytopenic purpura. European Journal of Haematology, 110(2), 157-160. https://doi.org/10.1111/ejh.13886

Vancouver

Comparon C, Galicier L, Rebibou JM, Coppo P, Benhamou Y. Preemptive cyclosporin A in immune‐mediated thrombotic thrombocytopenic purpura. European Journal of Haematology. 2023;110(2):157-160. doi:10.1111/ejh.13886

BibTeX
@article{Comparon2023,
  author = {Comparon, Celine and Galicier, Lionel and Rebibou, Jean Michel and Coppo, Paul and Benhamou, Ygal},
  title = {Preemptive cyclosporin A in immune‐mediated thrombotic thrombocytopenic purpura},
  journal = {European Journal of Haematology},
  year = {2023},
  volume = {110},
  number = {2},
  pages = {157--160},
  doi = {10.1111/ejh.13886}
}
Kostenlos starten →